Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: lenalidomide
Drug: Subcutaneous bortezomib
Drug: Dexamethasone

First Posted Date: 2014-08-18

Last Posted Date: 2020-07-17

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 42

Registration Number: NCT02219178

Locations: 🇮🇪
Midlands Regional Hospital, Tullamore, Ireland
🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪
Cork University Hospital, Cork, Ireland

and more 5 locations

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-08-13

Last Posted Date: 2024-07-22

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 210

Registration Number: NCT02215980

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-08-01

Last Posted Date: 2018-08-02

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 13

Registration Number: NCT02206503

Locations: 🇮🇹
Policlinico Umberto I, Rome, Italy

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Melphalan
Dietary Supplement: Ascorbic acid
Drug: PLD
Drug: Prednisone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2014-08-01

Last Posted Date: 2023-10-31

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 45

Registration Number: NCT02206425

Locations: 🇺🇸
James Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸
cCARE Fresno, Fresno, California, United States
🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States

and more 9 locations

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Phase 2

Active, not recruiting

Conditions: MULTIPLE MYELOMA (MM)

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-07-30

Last Posted Date: 2024-12-05

Lead Sponsor: Mario Boccadoro

Target Recruit Count: 477

Registration Number: NCT02203643

Locations: 🇮🇹
IRCCS--CROB --CROB di Rionero in di Rionero in Vulture, Rionero in Vulture, Italy

Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2014-07-30

Last Posted Date: 2023-07-03

Lead Sponsor: Stichting European Myeloma Network

Target Recruit Count: 36

Registration Number: NCT02204241

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Refractory Multiple Myeloma

Interventions: Drug: selinexor
Drug: carfilzomib
Drug: dexamethasone

First Posted Date: 2014-07-24

Last Posted Date: 2024-11-22

Lead Sponsor: University of Chicago

Target Recruit Count: 100

Registration Number: NCT02199665

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸
Mayo Clinic (AZ), Scottsdale, Arizona, United States
🇺🇸
Wayne State University Karmanos Cancer Institute, Detroit, Michigan, United States

and more 2 locations